GSK (GSK) Stock Forecast & Price Target

Q: What analysts cover GSK?

GSK has been rated by research analysts at Berenberg Bank , Citigroup , Deutsche Bank Aktiengesellschaft , HSBC , Jefferies Financial Group , Morgan Stanley , Royal Bank Of Canada , Weiss Ratings , and Wolfe Research in the past 90 days.

$46.50 -0.05 (-0.10%)

Closing price 03:59 PM Eastern

Extended Trading

$46.50 +0.01 (+0.02%)

As of 04:53 PM Eastern

Compare

GSK - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 12 Analyst Ratings

Sell
2

Hold
7

Buy
3

Based on 12 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 2 have given a sell rating, 7 have given a hold rating, 2 have given a buy rating, and 1 has given a strong buy rating for GSK.

Consensus Price Target

$61.00
31.20% Upside

According to the 12 analysts' twelve-month price targets for GSK, the average price target is $61.00. The highest price target for GSK is $70.00, while the lowest price target for GSK is $53.00. The average price target represents a forecasted upside of 31.20% from the current price of $46.50.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GSK Analyst Ratings Over Time

Type	Current Forecast 10/9/25 to 10/9/26	1 Month Ago 9/9/25 to 9/9/26	3 Months Ago 7/11/25 to 7/11/26	1 Year Ago 10/9/24 to 10/9/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	0 Buy rating(s)	3 Buy rating(s)	0 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	5 Hold rating(s)	7 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$61.00	$53.00	$53.00	$37.38
Forecasted Upside	31.20% Upside	8.92% Upside	0.43% Upside	-13.92% Downside
Consensus Rating	Hold	Hold	Hold	Reduce

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Healthcare Companies	Broader Market
Consensus Rating Score	2.17	2.32	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	31.51% Upside	919.45% Upside	19.66% Upside
News Sentiment Rating	Positive News See Recent GSK News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/9/2026	Wolfe Research 4 of 5 stars		Initiated Coverage	Outperform	$70.00	+50.48%
9/15/2026	Berenberg Bank 2 of 5 stars	Kerry Holford Not Rated	Set Target		$60.00	+19.84%
9/10/2026	HSBC 3 of 5 stars		Reiterated Rating	Hold
9/8/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform ➝ Sector Perform
8/25/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Underweight
7/30/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
7/29/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy (B-) ➝ Hold (C+)
7/24/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Graham Parry Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral
7/17/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
2/20/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Gordon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Underweight
Get the Latest News and Ratings for GSK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
2/9/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
11/25/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Underperform ➝ Neutral
10/30/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Wan Nurhayati Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$53.00	+13.21%
4/15/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Verdult Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral	$35.25	-1.07%
10/31/2024	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:17 PM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 8, 2026. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc is currently trading at $46.52, which is significantly below the average 12-month analyst price target of $56.50, suggesting substantial upside potential for investors who believe the market is undervaluing the company's recent pipeline additions and strategic initiatives.
The company has successfully expanded its oncology pipeline through recent high-profile deals, including a $10.6 billion acquisition of Nuvalent and a licensing agreement with HUTCHMED for HMPL-A830, which aims to diversify growth beyond its existing core products and address the upcoming patent cliff in its HIV franchise.
GSK plc offers an attractive dividend yield of 3.81%, supported by a recent increase in its quarterly dividend to $0.4515, providing a steady income stream for investors while the company maintains a payout ratio of 55.63% that leaves room for further growth investments.
Recent positive clinical data for ViiV Healthcare's long-acting HIV treatment Cabenuva, which met its primary endpoint in the phase IIIb CROWN study, reinforces the strength of GSK's HIV franchise and supports the company's strategy of managing its key therapeutic areas proactively.
With a low beta of 0.33, GSK plc exhibits lower volatility compared to the broader market, making it a potentially stable investment option for risk-averse investors seeking exposure to the pharmaceutical sector without significant price swings.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

The consensus rating from eleven brokerages covering GSK plc is "Hold," with two analysts issuing sell ratings, indicating that a significant portion of the financial community is cautious about the stock's near-term performance and potential risks.
GSK faces a significant patent cliff in its HIV franchise, which could lead to a substantial loss of revenue unless the company successfully executes its strategy of reinvesting cost savings into R&D and M&A to offset the impact of expiring patents.
Recent labor advocacy efforts to preserve jobs at GSK's Dresden vaccine plant in Germany highlight potential workforce and restructuring concerns, which could create execution costs or reputational pressure for the company.
The company's debt-to-equity ratio of 0.81 and current ratio of 0.82 suggest that GSK may face liquidity challenges or higher financial leverage, which could limit its flexibility in responding to market downturns or unexpected expenses.
Short interest in GSK plc has increased in recent months, with shares shorted rising to 14.65 million as of September 2026, indicating that some investors are betting against the stock's future performance and potentially signaling underlying concerns about the company's outlook.

GSK Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is $61.00, with a high forecast of $70.00 and a low forecast of $53.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 2 sell ratings, 7 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.

According to analysts, GSK's stock has a predicted upside of 31.20% based on their 12-month stock forecasts.

Over the previous 90 days, GSK's stock had 2 upgrades and 1 downgrade by analysts.

GSK has been rated by research analysts at Berenberg Bank, Citigroup, Deutsche Bank Aktiengesellschaft, HSBC, Jefferies Financial Group, Morgan Stanley, Royal Bank Of Canada, Weiss Ratings, and Wolfe Research in the past 90 days.

Analysts like GSK less than other "healthcare" companies. The consensus rating score for GSK is 2.17 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With GSK Recommendations

MarketBeat monitors more than a dozen sources for GSK analyst ratings, with the most recent rating issued on 10/9/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target